- Home
- HOLO vs INMB Comparison
HOLO vs INMB Comparison
Compare HOLO & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOLO | INMB |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.2M | 44.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HOLO | INMB |
|---|---|---|
| Price | $2.99 | $1.53 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.30 |
| AVG Volume (30 Days) | ★ 592.4K | 437.9K |
| Earning Date | 08-10-2023 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 13.81 | N/A |
| Revenue | ★ $44,840,587.00 | $50,000.00 |
| Revenue This Year | N/A | $264.29 |
| Revenue Next Year | N/A | $14,337.26 |
| P/E Ratio | $0.21 | ★ N/A |
| Revenue Growth | ★ 37.10 | 19.05 |
| 52 Week Low | $2.57 | $1.38 |
| 52 Week High | $153.60 | $11.64 |
Technical Indicators
Market Signals| Indicator | HOLO | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 39.58 |
| Support Level | $2.57 | $1.75 |
| Resistance Level | $3.04 | $1.66 |
| Average True Range (ATR) | 0.22 | 0.10 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 65.41 | 16.28 |
Price Performance
Historical ComparisonAbout HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.